Global Search | Novartis United States of America

Sort by

Relevance

Newest first

Oldest first

Hide Filters

Showing 719 results

Media Release / Jul 18, 2018

Novartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women

- Kisqali is now the only CDK4/6 inhibitor indicated in combination with an aromatase inhibitor as first-line treatment for pre-, peri- or postmenopausal women with HR+/HER2- advanced breast cancer…
Media Release / Jul 18, 2018

Novartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women
Media Release / Jul 12, 2018

Novartis launches the Galaxies of Hope app, a digital experience for the Neuroendocrine Tumor (NET) cancer community

- Galaxies of Hope offers a unique digital experience that engages users through the art of visual storytelling to connect with others to understand NET cancer - Using real-life stories and voices…
Media Release / Jul 12, 2018

Novartis launches the Galaxies of Hope app, a digital experience for the Neuroendocrine Tumor (NET) cancer community
Media Release / Jul 06, 2018

Sandoz Inc. and its affiliate, Novartis Pharmaceuticals Corporation, voluntarily recall select blister packages of products in the U.S. due to packaging requirements for child resistance

- Voluntary recall and notice of corrective action issued after discovering certain blister card packages distributed in the U.S. do not meet U.S. child-resistant packaging requirements- Certain lots…
Media Release / Jul 06, 2018

Sandoz Inc. and its affiliate, Novartis Pharmaceuticals Corporation, voluntarily recall select blister packages of products in the U.S. due to packaging requirements for child resistance
Media Release / Jun 27, 2018

Novartis and Amgen highlight findings from a large global patient survey revealing that worldwide approximately 60% of employed people with migraine missed, on average, a week of work in a month

- The My Migraine Voice survey involved more than 11,000 people globally, 10% of which were from the US, and highlights urgent need for better care for benefit of patients and society- In the US,…
Media Release / Jun 27, 2018

Novartis and Amgen highlight findings from a large global patient survey revealing that worldwide approximately 60% of employed people with migraine missed, on average, a week of work in a month
Media Release / Jun 27, 2018

Novartis announces funding for patient advocacy initiatives to support and empower metastatic breast cancer community

- STEP (Solutions to Empower Patients)™ Program helps nonprofit organizations deliver innovative solutions to patient communities - Funded programs aim to improve the experience of people living…
Media Release / Jun 27, 2018

Novartis announces funding for patient advocacy initiatives to support and empower metastatic breast cancer community

‹ Previous page
1
…
31
32
33
34
35
36
37
…
72
› Next page